Shares of Insmed INSM declined nearly 7% on Monday after the company announced that its chief financial officer (CFO), Sara Bonstein, will step down from her role effective Oct. 30.
The departure came as a surprise to investors, given Bonstein’s nearly seven-year tenure as CFO and her role during a significant period of Insmed’s growth and transformation.
While Insmed did not specify the reason for this transition, it stated that Bonstein’s departure is not related to any disagreement with the company concerning accounting practices, financial statements, internal controls or operations.
Although the leadership change introduces some uncertainty for investors, Insmed reaffirmed its 2026 revenue guidance. This suggests that management has not made any changes to its current financial outlook following the CFO transition.
Why Did INSM Stock Fall on CFO Departure News?
The sharp decline appears to be primarily due to investor uncertainty surrounding the unexpected departure of a long-serving senior executive. Bonstein oversaw Insmed’s finance organization during a period in which the company raised more than $4.2 billion in capital and transitioned into a commercial-stage biotech.
The timing of this departure may have further contributed to the negative reaction. Insmed is entering an important phase of growth, with Brinsupri rapidly scaling and the company targeting cash-flow positivity in 2027. Although Bonstein will remain in her role through the company’s third-quarter 2026 earnings release and conference call on Oct. 29, Insmed has already begun searching for her successor.
Year to date, shares of Insmed have lost 40% against the industry’s 3% growth.
Image Source: Zacks Investment Research
Insmed Reiterates 2026 Revenue Guidance
Despite the CFO transition, the company reaffirmed its full-year 2026 revenue guidance for its marketed products, Arikayce and Brinsupri.
Insmed continues to expect Brinsupri revenues between $1.25 billion and $1.40 billion, while Arikayce sales are in the range of $450-$470 million. Notably, the Brinsupri outlook was raised during its second-quarter results announcement from the previous guidance of at least $1 billion, while the Arikayce guidance remained unchanged.
While Arikayce is approved to treat refractory mycobacterium avium complex (MAC) lung disease in certain adults with limited or no treatment options, Brinsupri is approved for non-cystic fibrosis bronchiectasis (NCFB) in individuals aged 12 years and above.
INSM’s Zacks Rank
Insmed currently carries a Zacks Rank #3 (Hold).
Insmed, Inc. Price
Insmed, Inc. price | Insmed, Inc. Quote
Our Key Picks Among Biotech Stocks
Some better-ranked stocks in the sector include AC Immune ACIU and Viking Therapeutics VKTX, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimate for 2027 remained unchanged at 17 cents per share. ACIU shares have lost about 14% year-to-date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
Over the past 60 days, estimates for Viking’s 2026 loss per share have narrowed from $4.50 to $4.47, while those for 2027 have narrowed from $4.11 to $4.08. VKTX shares have lost nearly 17% year-to-date.
Viking’s earnings beat estimates in one of the trailing four quarters and missed the mark on the other three occasions, with the average negative surprise being 26.47%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Insmed, Inc. (INSM): Free Stock Analysis Report
Viking Therapeutics, Inc. (VKTX): Free Stock Analysis Report
AC Immune (ACIU): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).